Skip to main content
. Author manuscript; available in PMC: 2013 Apr 16.
Published in final edited form as: Vaccine. 2012 Mar 3;30(18):2811–2823. doi: 10.1016/j.vaccine.2012.02.036

Table 3.

Vaccine Name Vaccine Composition or Component Citation
Table 1A:
AdAg85A Adeno-5 vector expressing early secreted antigen Ag85A [26]
CFP/CpG protein Culture filtrate protein (CFP) plus CpG oligodeoxynucleotide adjuvant [27]
MVA85A Recombinant modified vaccinia virus Ankara (MVA) expressing early secreted antigen Ag85A [28]
Ag85A + MPL Early secreted antigen Ag85A in monophosphoryl lipid (MPL) A [31]
native HBHA + CT Native form of mycobacterial heparin-binding hemagglutinin plus cholera toxin (CT) adjuvant [32]
H1 + LTK63 Fusion protein of the two early secreted antigens, Ag85B and early secretory antigenic target (ESAT-6), plus non-toxic mucosal adjuvant derived from E. coli heat-labile enterotoxin [33]
AM-TT+ L3 Arabinomannan–tetanus toxoid conjugate (AM–TT) plus lipid-based suspension adjuvant [33]
H-kBCG + L3 Heat-killed BCG conjugate (H-kBCG) plus lipid-based suspension adjuvant [35]
CTA1-DD/ISCOM Mucosal combined adjuvant vector composed of immune-stimulating complexes (ISCOMs) and the cholera toxin-derived fusion protein CTA1-DD [35]
H56 + CAF01 New multistage vaccine that combines the early antigens Ag85B and 6-kDa early secretory antigenic target (ESAT-6) and the latency-associated protein Rv2660c in cationic liposomes [36]
ID93 + GLA-SE Recombinant fusion protein ID93 composed of the four M.tb. antigens Rv3619, Rv1813, Rv3620, and Rv2608 plus adjuvant of lipid formulated in a stable oil-in-water emulsion (GLA-SE) [37]
FP9.85A Recombinant fowlpox virus, FP9, expressing the major M.tb. secreted antigen antigen 85A [38]
HyVac4 Heterologous booster vaccine, using the antigensAg85B and TB10.4 (HyVac4) delivered as a fusion molecule and formulated in the adjuvant IC31 [40]
r30 Live recombinant BCG expressing the M.tb. 30-kDa major secretory protein (r30), also known as antigen 85B, α-antigen, or FbpB [41]
P-rAg85B Recombinant antigen 85B expressed in E. coli and encapsulated in poly(lactic-co -glycolic acid) particles [42]
Mtb72F + AS02A Fusion protein vaccine derived from the M.tb. proteins Mtb32 and Mtb39 formulated in the adjuvant AS02A [43]
HJV liposome/HSP65 DNA + IL-12 DNA DNA vaccine expressing mycobacterial heat shock protein 65 (HSP65) and interleukin 12 (IL-12) delivered by the hemagglutinating virus of Japan (HVJ)-envelope and -liposome [45]
Table 1B:
85B-ESAT6 + DDA + MPL Fusion antigen Ag85B-ESAT-6 adjuvanted in dimethyl dioctadecylammonium (DDA) bromide and monophosphoryl lipid (MPL) A [47]
CyaA-ESAT6 Bordetella pertussis adenylate cyclase (CyaA) toxoid plus early secreted antigenic target (ESAT-6) protein [49]
CyaA-85A Bordetella pertussis adenylate cyclase (CyaA) toxoid plus immunodominant regions of antigen 85A [49]
Table 1C:
pVAXhsp65 DNA vaccine containing the hsp65 heat shock protein gene from Mycobacterium leprae [7]
DNAE6 DNA vaccine expressing mycobacterial early secreted antigenic target (ESAT-6) protein [8]
Table 2A:
Apa/65/70 Cocktail of 3 DNA vaccines encoding Apa (Rv1860) [the alanine proline rich antigen] and heat shock proteins Hsp65 (Rv0440) and Hsp70 (Rv0350) [52]
PstS3-Ag85A DNA encoding PstS-3, M.tb. phosphate-binding transporter lipoprotein, and Ag85A, M.tb. early antigen [21]
DNA Ag85B, MPT-64, MPT-83 DNA encoding Ag85B, M.tb.early antigen, and immunogenic, major secreted proteins MPT-64 and MPT-83 (a surface lipoprotein) [53]
Table 2B:
rH4 Vaccine fusion molecule rH4 (Ag85B-TB10.4) in cationic liposomes (CAF01) [19]
E6-85 Early secreted antigenic target (ESAT-6) protein-antigen 85B fusion protein [18]
MVA/IL-15/5Mtb Recombinant modified vaccinia virus Ankara (MVA) overexpressing five M.tb. antigens 85A, 85B, ESAT6, HSP60 and Mtb39, as well as the molecular adjuvant IL-15 [18]
Ad-H4 Vaccine fusion molecule H4 (Ag85B-TB10.4) expressed in an adeno5 vector [19]
WAg520 Live attenuated M. bovis strain that has a kanamycin resistence gene in a coding region of Rv2136c [55]

This Table contains a more complete description of certain TB vaccine candidates identified in Tables 1 and 2 or of components that are part of the vaccine formulation. Vaccine names may occur in more than one table but are described only one time.